Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Annexon, Inc.ANNX · Entity 5011 | EVP & CHIEF FINANCIAL OFFICER | March 02, 2026 | March 04, 2026 |
| Boundless Bio, Inc.BOLD · Entity 7063 | Director | June 15, 2026 | June 15, 2026 |
| CHINOOK THERAPEUTICS, INC.ADRO · Entity 110632 | Chief Financial Officer | May 01, 2019 | May 03, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Annexon, Inc.
Report date March 02, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 170,700 |
Reported balance
After 2026-03-02 transaction · row 1
1 source rowRow 1 · 2026-03-02 · Sale · Disposed 5,565 · Balance 170,700 F1: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). F2: This transaction was executed in multiple trades in prices ranging from $5.34 to $5.57, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs").
F2: This transaction was executed in multiple trades in prices ranging from $5.34 to $5.57, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Boundless Bio, Inc.
Report date June 15, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.40 · Expires 2036-06-14 | Direct | 32,000 |
Reported balance
After 2026-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 32,000 · Balance 32,000 F1: The stock option shall vest in substantially equal monthly installments over the 12 months following June 15, 2026 (or, in the event the next annual meeting of the issuer's stockholders occurs prior to June 15, 2027, any remaining unvested portion of the stock option will vest on the date of such annual meeting), subject to the reporting person's continuing service on the issuer's board of directors through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option shall vest in substantially equal monthly installments over the 12 months following June 15, 2026 (or, in the event the next annual meeting of the issuer's stockholders occurs prior to June 15, 2027, any remaining unvested portion of the stock option will vest on the date of such annual meeting), subject to the reporting person's continuing service on the issuer's board of directors through such vesting date.
CHINOOK THERAPEUTICS, INC.
Report date May 01, 2019 · Filed May 03, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 135,155 |
Ending reported balance
After 2019-05-01 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2019-05-01 · Exercise / conversion · Acquired 4,226 · Balance 139,381 Row 2 · 2019-05-01 · Sale · Disposed 4,226 · Balance 135,155 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2019. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.10 to $4.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 3 · 2019-05-01 · Exercise / conversion · Acquired 2,232 · Balance 137,387 Row 4 · 2019-05-01 · Sale · Disposed 2,232 · Balance 135,155 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2019. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.10 to $4.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 5 · 2019-05-01 · Exercise / conversion · Acquired 12,144 · Balance 147,299 Row 6 · 2019-05-01 · Sale · Disposed 12,144 · Balance 135,155 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2019. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.10 to $4.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.82 · Expires 2023-11-26 | Direct | 42,258 |
Reported balance
After 2019-05-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-05-01 · Exercise / conversion · Disposed 4,226 · Balance 42,258 F3: The shares subject to the Option are fully vested and immediately exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2024-07-30 | Direct | 22,320 |
Reported balance
After 2019-05-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-05-01 · Exercise / conversion · Disposed 2,232 · Balance 22,320 F3: The shares subject to the Option are fully vested and immediately exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.45 · Expires 2025-01-09 | Direct | 121,440 |
Reported balance
After 2019-05-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-05-01 · Exercise / conversion · Disposed 12,144 · Balance 121,440 F3: The shares subject to the Option are fully vested and immediately exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2019.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.10 to $4.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: The shares subject to the Option are fully vested and immediately exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 08, 2019 Filed Apr 10, 2019 23:09 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,225 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001567619-19-008679 · doc1.xml · derivative · entry 7 Lew Jennifer · CIK 0001465994 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,484 Underlying: Common Stock · 4,225 shares Expires 2023-11-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the Option are fully vested and immediately exercisable. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 23:09 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | SaleCommon Stock | 12,144 | $4.07 | $49,468.58 |
DisclosureSEC source: 0001567619-19-008679 · doc1.xml · nonDerivative · entry 6 Lew Jennifer · CIK 0001465994 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,155 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.99 to $4.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 23:09 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionCommon Stock | 12,144 | $1.45 | $17,608.80 |
DisclosureSEC source: 0001567619-19-008679 · doc1.xml · nonDerivative · entry 5 Lew Jennifer · CIK 0001465994 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 23:09 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | SaleCommon Stock | 2,232 | $4.07 | $9,087.14 |
DisclosureSEC source: 0001567619-19-008679 · doc1.xml · nonDerivative · entry 4 Lew Jennifer · CIK 0001465994 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,155 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.99 to $4.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 23:09 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionCommon Stock | 2,232 | $1.00 | $2,232.00 |
DisclosureSEC source: 0001567619-19-008679 · doc1.xml · nonDerivative · entry 3 Lew Jennifer · CIK 0001465994 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,387 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 23:09 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | SaleCommon Stock | 4,225 | $4.08 | $17,219.41 |
DisclosureSEC source: 0001567619-19-008679 · doc1.xml · nonDerivative · entry 2 Lew Jennifer · CIK 0001465994 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,155 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.99 to $4.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 23:09 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionCommon Stock | 4,225 | $0.82 | $3,464.50 |
DisclosureSEC source: 0001567619-19-008679 · doc1.xml · nonDerivative · entry 1 Lew Jennifer · CIK 0001465994 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,380 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 21:42 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $3.88 | $0.00 |
DisclosureSEC source: 0001567619-19-005105 · doc1.xml · derivative · entry 1 Lew Jennifer · CIK 0001465994 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2029-02-18 F1 · derivative.exercise_date: The shares subject to the Option vest in 48 equal monthly installments from the vesting commencement date of February 19, 2019. Read SEC document |
| December 12, 2018 Filed Dec 14, 2018 21:19 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | SaleCommon Stock | 1,035 | $2.93 | $3,034.62 |
DisclosureSEC source: 0001567619-18-008015 · doc1.xml · nonDerivative · entry 1 Lew Jennifer · CIK 0001465994 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,155 F1 · kind: The shares were sold to cover the tax obligation that occurred upon the vesting of RSUs. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.72 to $3.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 13, 2018 Filed Sep 14, 2018 23:27 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | SaleCommon Stock | 5,623 | $6.50 | $36,545.56 |
DisclosureSEC source: 0001567619-18-002682 · doc1.xml · nonDerivative · entry 2 Lew Jennifer · CIK 0001465994 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,190 F2 · kind: The shares were sold to cover the tax obligation that occurred upon the vesting of RSUs. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.25 to $6.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 12, 2018 Filed Sep 14, 2018 23:27 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | GrantCommon Stock | 67,825 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-002682 · doc1.xml · nonDerivative · entry 1 Lew Jennifer · CIK 0001465994 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,813 F1 · shares: Represents grant of restricted stock units payable in common stock that vest in four equal annual installments from the grant date of September 12, 2018. Read SEC document |
| February 08, 2018 Filed Feb 13, 2018 01:17 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | GrantStock Option (right to buy) · Derivative | 135,650 | $0.00 Strike: $6.05 | $0.00 |
DisclosureSEC source: 0001209191-18-009386 · doc4.xml · derivative · entry 1 Lew Jennifer · CIK 0001465994 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,650 Underlying: Common Stock · 135,650 shares Expires 2028-02-07 F1 · derivative.exercise_date: The shares subject to the Option vest in 48 equal monthly installments from the vesting commencement date of February 8, 2018. Read SEC document |
| December 11, 2017 Filed Dec 14, 2017 01:16 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | GrantCommon Stock | 11,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-065521 · doc4.xml · nonDerivative · entry 1 Lew Jennifer · CIK 0001465994 · Sr. Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,988 F1 · shares: Represents grant of restricted stock units payable in common stock that vest in four equal annual installments from the grant date of December 11, 2017. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 00:57 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,600 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001209191-17-063678 · doc4.xml · derivative · entry 3 Lew Jennifer · CIK 0001465994 · Sr. Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,709 Underlying: Common Stock · 6,600 shares Expires 2023-11-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the Option are fully vested and immediately exercisable. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 00:57 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | SaleCommon Stock | 6,600 | $9.46 | $62,432.70 |
DisclosureSEC source: 0001209191-17-063678 · doc4.xml · nonDerivative · entry 2 Lew Jennifer · CIK 0001465994 · Sr. Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,338 F1 · kind: The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.25 to $9.525, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 00:57 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionCommon Stock | 6,600 | $0.82 | $5,412.00 |
DisclosureSEC source: 0001209191-17-063678 · doc4.xml · nonDerivative · entry 1 Lew Jennifer · CIK 0001465994 · Sr. Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,938 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 23:42 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,600 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001209191-17-061613 · doc4.xml · derivative · entry 3 Lew Jennifer · CIK 0001465994 · Sr. Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,309 Underlying: Common Stock · 6,600 shares Expires 2023-11-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to the Option are fully vested and immediately exercisable. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 23:42 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | SaleCommon Stock | 6,600 | $8.95 | $59,070.00 |
DisclosureSEC source: 0001209191-17-061613 · doc4.xml · nonDerivative · entry 2 Lew Jennifer · CIK 0001465994 · Sr. Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,338 F1 · kind: The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2017. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 23:42 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionCommon Stock | 6,600 | $0.82 | $5,412.00 |
DisclosureSEC source: 0001209191-17-061613 · doc4.xml · nonDerivative · entry 1 Lew Jennifer · CIK 0001465994 · Sr. Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,938 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 02, 2017 Filed Oct 5, 2017 00:21 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,600 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001209191-17-056046 · doc4.xml · derivative · entry 3 Lew Jennifer · CIK 0001465994 · Sr. Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,909 Underlying: Common Stock · 6,600 shares Expires 2023-11-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Twenty-five percent of the shares subject to the Option vested on the first anniversary of the vesting commencement date of October 25, 2014, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| October 02, 2017 Filed Oct 5, 2017 00:21 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | SaleCommon Stock | 6,600 | $10.61 | $69,994.98 |
DisclosureSEC source: 0001209191-17-056046 · doc4.xml · nonDerivative · entry 2 Lew Jennifer · CIK 0001465994 · Sr. Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,338 F1 · kind: The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.40 to $10.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 02, 2017 Filed Oct 5, 2017 00:21 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionCommon Stock | 6,600 | $0.82 | $5,412.00 |
DisclosureSEC source: 0001209191-17-056046 · doc4.xml · nonDerivative · entry 1 Lew Jennifer · CIK 0001465994 · Sr. Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,938 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 13, 2017 Filed Sep 15, 2017 01:21 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | SaleCommon Stock | 3,557 | $10.99 | $39,076.49 |
DisclosureSEC source: 0001209191-17-052893 · doc4.xml · nonDerivative · entry 2 Lew Jennifer · CIK 0001465994 · Sr. Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,338 F2 · kind: The shares were sold to cover the tax obligation that occurred upon the vesting of an RSU. Read SEC document |
| September 12, 2017 Filed Sep 15, 2017 01:21 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | GrantCommon Stock | 23,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-052893 · doc4.xml · nonDerivative · entry 1 Lew Jennifer · CIK 0001465994 · Sr. Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,895 F1 · shares: Represents grant of restricted stock units payable in common stock that vest in four equal annual installments from the grant date of September 12, 2017. Read SEC document |
| September 01, 2017 Filed Sep 6, 2017 20:29 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,600 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001209191-17-051624 · doc4.xml · derivative · entry 3 Lew Jennifer · CIK 0001465994 · Sr. Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,509 Underlying: Common Stock · 6,600 shares Expires 2023-11-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Twenty-five percent of the shares subject to the Option vested on the first anniversary of the vesting commencement date of October 25, 2014, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| September 01, 2017 Filed Sep 6, 2017 20:29 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | SaleCommon Stock | 6,600 | $11.70 | $77,242.44 |
DisclosureSEC source: 0001209191-17-051624 · doc4.xml · nonDerivative · entry 2 Lew Jennifer · CIK 0001465994 · Sr. Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,595 F1 · kind: The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.50 to $12.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 01, 2017 Filed Sep 6, 2017 20:29 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionCommon Stock | 6,600 | $0.82 | $5,412.00 |
DisclosureSEC source: 0001209191-17-051624 · doc4.xml · nonDerivative · entry 1 Lew Jennifer · CIK 0001465994 · Sr. Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,195 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2017 Filed Aug 9, 2017 23:41 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,600 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001209191-17-048355 · doc4.xml · derivative · entry 3 Lew Jennifer · CIK 0001465994 · Sr. Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,109 Underlying: Common Stock · 6,600 shares Expires 2023-11-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Twenty-five percent of the shares subject to the Option vested on the first anniversary of the vesting commencement date of October 25, 2014, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| August 07, 2017 Filed Aug 9, 2017 23:41 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | SaleCommon Stock | 6,600 | $12.17 | $80,290.32 |
DisclosureSEC source: 0001209191-17-048355 · doc4.xml · nonDerivative · entry 2 Lew Jennifer · CIK 0001465994 · Sr. Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,595 F1 · kind: The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.98 to $12.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 07, 2017 Filed Aug 9, 2017 23:41 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionCommon Stock | 6,600 | $0.82 | $5,412.00 |
DisclosureSEC source: 0001209191-17-048355 · doc4.xml · nonDerivative · entry 1 Lew Jennifer · CIK 0001465994 · Sr. Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,195 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 03, 2017 Filed Jul 6, 2017 23:13 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001209191-17-044235 · doc4.xml · derivative · entry 3 Lew Jennifer · CIK 0001465994 · Sr. Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,709 Underlying: Common Stock · 12,000 shares Expires 2023-11-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Twenty-five percent of the shares subject to the Option vested on the first anniversary of the vesting commencement date of October 25, 2014, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| July 03, 2017 Filed Jul 6, 2017 23:13 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | SaleCommon Stock | 12,000 | $11.14 | $133,632.00 |
DisclosureSEC source: 0001209191-17-044235 · doc4.xml · nonDerivative · entry 2 Lew Jennifer · CIK 0001465994 · Sr. Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,595 F1 · kind: The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.85 to $11.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 03, 2017 Filed Jul 6, 2017 23:13 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionCommon Stock | 12,000 | $0.82 | $9,840.00 |
DisclosureSEC source: 0001209191-17-044235 · doc4.xml · nonDerivative · entry 1 Lew Jennifer · CIK 0001465994 · Sr. Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,595 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 28, 2017 Filed Jun 30, 2017 22:03 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001209191-17-042593 · doc4.xml · derivative · entry 3 Lew Jennifer · CIK 0001465994 · Sr. Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,709 Underlying: Common Stock · 12,000 shares Expires 2023-11-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Twenty-five percent of the shares subject to the Option vested on the first anniversary of the vesting commencement date of October 25, 2014, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| June 28, 2017 Filed Jun 30, 2017 22:03 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | SaleCommon Stock | 12,000 | $11.19 | $134,235.60 |
DisclosureSEC source: 0001209191-17-042593 · doc4.xml · nonDerivative · entry 2 Lew Jennifer · CIK 0001465994 · Sr. Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,595 F1 · kind: The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.00 to $11.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 28, 2017 Filed Jun 30, 2017 22:03 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionCommon Stock | 12,000 | $0.82 | $9,840.00 |
DisclosureSEC source: 0001209191-17-042593 · doc4.xml · nonDerivative · entry 1 Lew Jennifer · CIK 0001465994 · Sr. Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,595 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2017 Filed Jun 15, 2017 01:13 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | GrantStock Option (right to buy) · Derivative | 23,300 | $0.00 Strike: $10.75 | $0.00 |
DisclosureSEC source: 0001209191-17-039999 · doc4.xml · derivative · entry 1 Lew Jennifer · CIK 0001465994 · Sr. Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,300 Underlying: Common Stock · 23,300 shares Expires 2027-06-11 F1 · derivative.exercise_date: The shares subject to the Option vest in 48 equal monthly installments from the vesting commencement date of June 12, 2017. Read SEC document |
| December 12, 2016 Filed Dec 15, 2016 02:07 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | GrantStock Option (right to buy) · Derivative | 27,800 | $0.00 Strike: $11.15 | $0.00 |
DisclosureSEC source: 0001209191-16-155283 · doc4.xml · derivative · entry 1 Lew Jennifer · CIK 0001465994 · Sr. Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,800 Underlying: Common Stock · 27,800 shares Expires 2026-12-11 F1 · derivative.exercise_date: The shares subject to the Option vest in 48 equal monthly installments from the vesting commencement date of December 12, 2016. Read SEC document |
| November 10, 2016 Filed Nov 15, 2016 00:02 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,910 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001209191-16-149953 · doc4.xml · derivative · entry 3 Lew Jennifer · CIK 0001465994 · Sr. Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,709 Underlying: Common Stock · 10,910 shares Expires 2023-11-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Twenty-five percent of the shares subject to the Option vests on the first anniversary of the vesting commencement date of October 25, 2014, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| November 10, 2016 Filed Nov 15, 2016 00:02 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | SaleCommon Stock | 10,910 | $14.95 | $163,104.50 |
DisclosureSEC source: 0001209191-16-149953 · doc4.xml · nonDerivative · entry 2 Lew Jennifer · CIK 0001465994 · Sr. Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,595 F1 · kind: The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 17, 2016. Read SEC document |
| November 10, 2016 Filed Nov 15, 2016 00:02 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionCommon Stock | 10,910 | $0.82 | $8,946.20 |
DisclosureSEC source: 0001209191-16-149953 · doc4.xml · nonDerivative · entry 1 Lew Jennifer · CIK 0001465994 · Sr. Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,505 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 19, 2016 Filed Sep 21, 2016 20:57 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,455 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001209191-16-142282 · doc4.xml · derivative · entry 3 Lew Jennifer · CIK 0001465994 · Sr. Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,619 Underlying: Common Stock · 5,455 shares Expires 2023-11-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Twenty-five percent of the shares subject to the Option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| September 19, 2016 Filed Sep 21, 2016 20:57 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | SaleCommon Stock | 6,360 | $14.95 | $95,082.00 |
DisclosureSEC source: 0001209191-16-142282 · doc4.xml · nonDerivative · entry 2 Lew Jennifer · CIK 0001465994 · Sr. Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,595 F1 · kind: The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 19, 2015. Read SEC document |
| September 19, 2016 Filed Sep 21, 2016 20:57 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionCommon Stock | 5,455 | $0.82 | $4,473.10 |
DisclosureSEC source: 0001209191-16-142282 · doc4.xml · nonDerivative · entry 1 Lew Jennifer · CIK 0001465994 · Sr. Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,955 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 12, 2016 Filed Sep 14, 2016 20:18 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | GrantCommon Stock | 37,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-141398 · doc4.xml · nonDerivative · entry 1 Lew Jennifer · CIK 0001465994 · Sr. Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,500 F1 · shares: Represents grant of restricted stock units payable in common stock that vest in four equal annual installments from the grant date of September 12, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.